These cases demonstrate the remarkable efficacy and tolerability of T-DXd in this uncommon and challenging clinical scenario, highlighting its potential as a valuable therapeutic option in HER2-low breast cancer with BMI. This evidence concerns the gene ERBB2 and breast carcinoma.